Biohaven Ltd. Class Action Lawsuit - BHVN

The filed complaint alleges that Biohaven Ltd. made materially false and/or misleading statements and/or failed to disclose that: (i) The company's product candidate, troriluzole’s regulatory prospects as a treatment for SCA, and/or the sufficiency of data that Biohaven submitted in support of troriluzole’s regulatory approval for this indication, were overstated; (ii) BHV-7000’s efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (iii) all the foregoing, once revealed, was likely to have a significant negative impact on Biohaven’s business and financial condition; and (iv) as a result, defendants’ public statements were materially false and misleading at all relevant times.

In order to be eligible to join the BHVN class action lawsuit, you must have incurred a loss on shares of Biohaven Ltd. purchased during the class period listed above.

If you suffered a loss in Biohaven Ltd. during the relevant time frame or pursuant to the relevant offering(s), you have until September 12, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.